الفهرس 
Hepatocellular carcinoma (HCC)Only 14 pages are availabe for public view
 |  | from | 73 |  |  |
| | | from | 73 | | |
Abstract
HCC is the most common type of primary liver cancer in adults, and is the most common cause of death in people with cirrhosis. It occurs in the setting of chronic liver inflammation, and is most closely linked to chronic viral hepatitis infection (hepatitis B or C) or exposure to toxins such as alcohol or aflatoxin. HCC, like any other cancer, develops when there is a mutation to the cellular machinery that causes the cell to replicate at a higher rate and/or results in the cell avoiding apoptosis.
Although they can be small and slow growing, HCC tumors can be successfully treated by aggressive surgery, patients often lose the window for surgical resection due to the lack of effective tools for early diagnosis which results in very low 5-year survival rates. Therefore, to improve the prognosis of HCC, it is important and critical to develop specific and sensitive diagnostic biomarkers for HCC The MALAT1 lnc RNA with >8000 bp located on chromosome 11q13.1, was first identified as an oncogene in non-small-cell lung cancer (NSCLC) because of its functional role in promoting metastasis Over expression of MALAT1 was shown to exhibit marked effects on tumor cell proliferation, migration, invasion, and apoptosis in HCC. The aim of this work was to assess the association between MALAT1 gene single nucleotide polymorphisms and hepatocellular carcinoma risk.
This study was carried out on Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Menoufia University and Hepatology Department, National liver Institute, Menoufia University. It included one hundred twenty subjects, classified into three groups; group I included: forty patients with hepatocellular carcinoma on top of HCV, group II: Included forty patients with hepatocellular carcinoma on top of HBV, group III included forty patients age and gender matched apparently healthy individuals served as control group. Patients with combined HCV and HBV infections, history of liver transplantation, other malignant neoplasm, HIV, chronic lung diseases, and renal insufficiency were excluded from this study. All participants were subjected to the following: thorough history taking history, clinical examination, abdominal ultrasound, Triphasic CT scan or MRI for patients with HCC, Liver function tests, HCV antibodies, HbsAg and AFP. Genotyping of MALAT1 (rs619586 and rs3200401) SNPs by real time is done by real time PCR (allelic discrimination assay)